CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Increasing prevalence of fungal infection
3.6.1.2. Rising awareness levels pertaining to myriad fungal infections
3.6.1.3. Favorable government funds to combat the antifungal diseases
3.6.2. Restraints
3.6.2.1. Growing population with antifungal drug resistance
3.6.2.2. Presence of counterfeit drugs and side effects of antifungal drugs
3.6.3. Opportunities
3.6.3.1. Patent expirations and increasing funding from public & private organizations
CHAPTER 4 ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. SUPERFICIAL ANTIFUNGAL INFECTION
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. SYSTEMIC ANTIFUNGAL INFECTION
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
CHAPTER 5 ANTIFUNGAL DRUGS MARKET, BY DRUG TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ECHINOCANDINS
5.2.1. Market size and forecast
5.2.2. Micafungin
5.2.2.1. Market size and forecast
5.2.3. Caspofungin
5.2.3.1. Market size and forecast
5.2.4. Anidulafungin
5.2.4.1. Market size and forecast
5.2.5. Others
5.2.5.1. Market size and forecast
5.3. AZOLES
5.3.1. Market size and forecast
5.3.1. Imidazoles
5.3.1.1. Market size and forecast
5.3.2. Voricanazole
5.3.2.1. Market size and forecast
5.3.3. Thiazoles
5.3.3.1. Market size and forecast
5.3.4. Others
5.3.4.1. Market size and forecast
5.4. POLYENES
5.4.1. Market size and forecast
5.4.2. Amphotericin B
5.4.2.1. Market size and forecast
5.4.3. Candicidin
5.4.3.1. Market size and forecast
5.4.4. Hamycin
5.4.4.1. Market size and forecast
5.4.5. Natamycin
5.4.5.1. Market size and forecast
5.4.6. Others
5.4.6.1. Market size and forecast
5.5. ALLYLAMINES
5.5.1. Market size and forecast
5.5.1. Terbinafine
5.5.1.1. Market size and forecast
5.5.2. Butenafine
5.5.2.1. Market size and forecast
5.5.3. Naftifine
5.5.3.1. Market size and forecast
5.6. OTHERS
5.6.1. Market size and forecast
CHAPTER 6 ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. ASPERGILLOSIS
6.2.1. Market size and forecast
6.3. DERMATOPHYTOSIS
6.3.1. Market size and forecast
6.4. CANDIDIASIS
6.4.1. Market size and forecast
6.5. OTHERS
6.5.1. Market size and forecast
CHAPTER 7 ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. POWDER
7.2.1. Market size and forecast
7.3. OINTMENTS
7.3.1. Market size and forecast
7.4. DRUGS
7.4.1. Market size and forecast
7.5. OTHERS
7.5.1. Market size and forecast
CHAPTER 8 ANTIFUNGAL DRUGS MARKET, BY GEOGRAPHY
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. NORTH AMERICA
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
8.2.3.1. U.S. market size and forecast
8.2.3.2. Mexico market size and forecast
8.2.3.3. Canada market size and forecast
8.3. EUROPE
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
8.3.3.1. UK market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. Germany market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast
8.4. ASIA-PACIFIC
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. Rest of Asia-Pacific market size and forecast
8.5. LAMEA
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast
8.5.3.1. Brazil market size and forecast
8.5.3.2. Argentina market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1. PFIZER INC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments
9.2. SANOFI S.A
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments
9.3. GILEAD SCIENCES INC.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments
9.4. MERCK & CO., INC.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments
9.5. NOVARTIS INTERNATIONAL AG
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments
9.6. ABBOTT LABORATORIES
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments
9.7. BAYER AG
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments
9.8. SCYNEXIS INC.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments
9.9. ENZON PHARMACEUTICALS INC.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments
9.10. GLAXOSMITHKLINE PLC
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments
